Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
23 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
134 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
25
25 articles ont été cités au moins 25fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
2 265
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
58
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
37
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Nantes Université
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Early life stages of Aquitanian pike Esox aquitanicus (Teleostei, Esocidae): first description of morphological development and trials of rearing
2026ArticleKnowledge and Management of Aquatic Ecosystems
Resolving the Structural Duality of Graphene Grain Boundaries
2025ArticleAdvanced Materials
Wide Electrical Tunability of the Valley Splitting in a Doubly Gated Silicon-on-Insulator Quantum Well
2025ArticleNano Letters
HR-STEM-iDPC study of Graphene on SiC substrate : Comparison of in-situ and ex-situ hydrogenation treatment
2025CongrèsSfµ 2025
Adaptation of French general practitioners for the management of nursing home patients during COVID-19 in 2020: a multilevel analysis
2024ArticleBMC Primary Care
Effectiveness of comprehensive geriatric assessment adapted to primary care when provided by a nurse or a general practitioner: the CEpiA cluster-randomised trial
2024ArticleBMC Medicine
Impact of Quaternary Ammonium Ions on the Properties of 2D MoS2 Synthesized via Electrochemical Exfoliation
2024CongrèsNanoteC24
Observation of Kekulé vortices around hydrogen adatoms in graphene
2024ArticleNature Communications
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CABINET DU DR VINCENT RENARD
17 PLACE DES MARRONNIERS, 94100 ST MAUR DES FOSSES
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
JAMA oncology · 2023
ImportanceAlthough immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and PD-1 ligand 1 have improved the outcome for many cancer types, the majority of patients fails to respond to ICI monotherapy. Hypofractionated radiotherapy has the potential to improve the therapeutic ratio of ICIs.ObjectiveTo assess the addition of radiotherapy to ICIs compared with ICI monotherapy in patients with advanced solid tumors.Design, Setting, and ParticipantsThis open-label, multicenter, randomized phase 2 trial was conducted in 5 Belgian hospitals and enrolled participants between March 2018 and October 2020. Patients 18 years or older with locally advanced or metastatic melanoma, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, or non–small cell lung carcinoma were eligible. A total of 99 patients were randomly assigned to either the control arm (n = 52) or the experimental arm (n = 47). Of those, 3 patients (1 in the control arm vs 2 in the experimental arm) withdrew consent and thus were not included in the analysis. Data analyses were performed between April 2022 and March 2023.InterventionsPatients were randomized (1:1) to receive anti–PD-1/PD-1 ligand 1 ICIs alone as per standard of care (control arm) or combined with stereotactic body radiotherapy 3 × 8 gray to a maximum of 3 lesions prior to the second or third ICI cycle, depending on the frequency of administration (experimental arm). Randomization was stratified according to tumor histologic findings and disease burden (3 and fewer or more than 3 cancer lesions).Main Outcomes and MeasuresThe primary end point was progression-free survival (PFS) as per immune Response Evaluation Criteria in Solid Tumors. Key secondary end points included overall survival (OS), objective response rate, local control rate, and toxic effects. Efficacy was assessed in the intention-to-treat population, while safety was evaluated in the as-treated population.ResultsAmong 96 patients included in the analysis (mean age, 66 years; 76 [79%] female), 72 (75%) had more than 3 tumor lesions and 65 (68%) had received at least 1 previous line of systemic treatment at time of inclusion. Seven patients allocated to the experimental arm did not complete the study-prescribed radiotherapy course due to early disease progression (n = 5) or intercurrent illness (n = 2). With a median (range) follow-up of 12.5 (0.7-46.2) months, median PFS was 2.8 months in the control arm compared with 4.4 months in the experimental arm (hazard ratio, 0.95; 95% CI, 0.58-1.53; P = .82). Between the control and experimental arms, no improvement in median OS was observed (11.0 vs 14.3 months; hazard ratio, 0.82; 95% CI, 0.48-1.41; P = .47), and objective response rate was not statistically significantly different (22% vs 27%; P = .56), despite a local control rate of 75% in irradiated patients. Acute treatment-related toxic effects of any grade and grade 3 or higher occurred in 79% and 18% of patients in the control arm vs 78% and 18% in the experimental arm, respectively. No grade 5 adverse events occurred.Conclusions and RelevanceThis phase 2 randomized clinical trial demonstrated that while safe, adding subablative stereotactic radiotherapy of a limited number of metastatic lesions to ICI monotherapy failed to show improvement in PFS or OS.Trial RegistrationClinicalTrials.gov Identifier: NCT03511391
European journal of cancer (Oxford, England : 1990) · 2017
Physical review letters · 2018
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2025 · Journal Article
Van Goethem V, Dierickx S, Matthys O, Deliens L, et al.
BMC medicine · 2024 · Journal Article
Orcel V, Banh L, Bastuji-Garin S, Renard V, et al.
JAMA oncology · 2023 · Randomized Controlled Trial
Spaas M, Sundahl N, Kruse V, Rottey S, et al.
BMC cancer · 2021 · Clinical Trial Protocol
Spaas M, Sundahl N, Hulstaert E, Kruse V, et al.
Breast cancer research and treatment · 2019 · Clinical Trial, Phase II
Fontaine C, Renard V, Van den Bulk H, Vuylsteke P, et al.
BMJ open · 2018 · Journal Article
Ferrat E, Bastuji-Garin S, Paillaud E, Caillet P, et al.
European journal of cancer (Oxford, England : 1990) · 2017 · Clinical Trial, Phase III
Marth C, Vergote I, Scambia G, Oberaigner W, et al.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2016 · Journal Article
Le Breton J, Ferrat É, Attali C, Bercier S, et al.
The British journal of general practice : the journal of the Royal College of General Practitioners · 2013 · Journal Article
Le Corvoisier P, Renard V, Roudot-Thoraval F, Cazalens T, et al.
Journal of the Medical Library Association : JMLA · 2018 · Journal Article
Barreau D, Bouton C, Renard V, Fournier JP
The British journal of general practice : the journal of the Royal College of General Practitioners · 2017 · Journal Article
Boussageon R, Pouchain D, Renard V
Presse medicale (Paris, France : 1983) · 2015 · Letter
Letrilliart L, Pouchain D, Le Reste JY, Renard V
Physical review letters · 2021 · Journal Article
Mesple F, Missaoui A, Cea T, Huder L, et al.
Physical review letters · 2018 · Journal Article
Huder L, Artaud A, Le Quang T, de Laissardière GT, et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2009 · Case Reports
Amant F, Coosemans A, Renard V, Everaert E, et al.
BMJ open · 2023 · Multicenter Study
Phan TT, Mirat W, Brossier S, Boutin E, et al.
The British journal of general practice : the journal of the Royal College of General Practitioners · 2021 · Journal Article
Ferrat E, Fabre J, Galletout P, Boutin E, et al.
BMC medicine · 2024 · Journal Article
Orcel V, Banh L, Bastuji-Garin S, Renard V, et al.
BMJ open · 2018 · Journal Article
Ferrat E, Bastuji-Garin S, Paillaud E, Caillet P, et al.
BMC pharmacology & toxicology · 2015 · Journal Article
Lambrechts S, Lambrechts D, Despierre E, Van Nieuwenhuysen E, et al.
European urology · 2023 · Journal Article
Saad F, de Bono J, Barthélémy P, Dorff T, et al.
Trials · 2013 · Journal Article
Pouchain D, Lièvre M, Huas D, Lebeau JP, et al.
BMC medicine · 2024 · Journal Article
Orcel V, Banh L, Bastuji-Garin S, Renard V, et al.
Processed ship-based Navigation Data acquired during the Vema expedition V2710 (1970)
This data set was acquired with a ship-based Navigation system during Vema expedition V2710 conducted in 1970 (Chief Scientist: Dr. Vincent Renard). These data files are of Text File (ASCII) format and include Navigation
Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial
Abstract Background While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for various tumor types has led to considerable improvements in clinical outcome, the majority of patients still fa
Sample CH31-DR02-112
Sample CH31-DR02-112 collected during MIDLANTE CH31 cruise (sampling method: Rock dredge), stored in IFREMER repository.
Sample CH31-DR02-122
Sample CH31-DR02-122 collected during MIDLANTE CH31 cruise (sampling method: Rock dredge), stored in IFREMER repository.
Sample CH31-DR03-124
Sample CH31-DR03-124 collected during MIDLANTE CH31 cruise (sampling method: Rock dredge), stored in IFREMER repository.
Sample CH31-DR01-101-B
Sample CH31-DR01-101-B collected during MIDLANTE CH31 cruise (sampling method: Rock dredge), stored in IFREMER repository.
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Rhumatologie · 1967 · Journal Article
Renard V, Renard-Lefebvre AM
Revue de chirurgie orthopedique et reparatrice de l'appareil moteur · 1966 · Journal Article
Renard V, Renard AM, Juster M
Acta orthopaedica Belgica · 1965 · Journal Article
Renard V, Renard AM